Delafloxacin (Quofenix®) licensed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||11/08/2020|
|Rapid review completed||19/11/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of delafloxacin compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|